Comparison of Serum Level and IL-18 Gene Expression and Reactive Protein in Patients with Type 2 Diabetes with Metabolic Syndrome and Healthy People

Metabolic syndrome is a common clinical anomaly, with an increased risk of developing type 2 diabetes and cardiovascular risk factors. Increased inflammatory mediators, such as reactive protein,as well as the inflammatory cytokines can be associated with the incidence and progression of metaboli syndrome and type 2 diabetes.
 

This study was performed on 35 male and female patients with an average age of 55 years, type 2 diabetes mellitus with metabolic syndrome and 35 healthy subjects as control group. Separated serum samples were kept at -20 ° C for quantitative evaluation of serum IL-18 by ELISA kit and C-reactive protein. RNA extraction from cells was performed by JenaBioscience kit and finally Gene expression assay was performed quantitatively using Real Time RTPCR.
 

The mean serum levels of IL-18 were significantly increased (P=0.008), and serum reactive protein (P<0.001) was significantly increased in patients with type 2 diabetes mellitus with metabolic syndrome compared with healthy subjects. Also, expression of IL-18 gene (P=0.003) in lymphocyte cells of type II diabetes patients with metabolic syndrome was significantly higher than healthy subjects.
 

The present study showed that patients with type 2 diabetes mellitus with metabolic syndrome have high levels of inflammatory factors such as IL-18 in their serum. it can be concluded that serum levels of IL-18, C-reactive protein and IL-18 expression play an important role in inflammatory response and progression. Type 2 diabetes and metabolic syndrome.